Methods of inducing an immune response

US7628989B2 · kind B2 · utility

Assignee

• Latency, LLC · US

Inventors

• Aya Jakobovits · Beverly Hills, US
• Pia M. Challita-Eid · Calabasas, US
• Mary Faris · Los Angeles, US
• Wangmao Ge · Tampa, US
• Rene S. Hubert · Los Angeles, US
• Karen Jane Meyrick Morrison · Santa Monica, US
• Robert Kendall Morrison · Santa Monica, US
• Arthur B. Raitano · Los Angeles, US
• Daniel Afar · Santa Monica, US

Key dates

• Filing date: Jun 17, 2005
• Grant date: Dec 8, 2009
• Expiry date: Nov 9, 2025

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.